Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 1
1 (25.0%)Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Jenny C. Chang, MD
- Registration Number
- NCT02725541
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Jenny C. Chang, MD
- Target Recruit Count
- 24
- Registration Number
- NCT02073916
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
Phase 2
Withdrawn
- Conditions
- Breast Cancer
- Interventions
- Drug: taxane-based chemotherapyDrug: Anthracycline based chemotherapy
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Jenny C. Chang, MD
- Registration Number
- NCT02067416
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Jenny C. Chang, MD
- Target Recruit Count
- 24
- Registration Number
- NCT01931163
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Willowbrook, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
News
No news found